Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  Issue: January 2009  |  January 1, 2009

Clinical Presentation and Drug Characteristics

Patients may present with mild fatigue to fulminant rhabdomyolysis requiring hospitalization. The most common symptoms are myalgia, weakness, low back and proximal muscle pain or generalized body aches, and/or dyspnea.4 Fatigue and muscle pain are often the most common chief complaint for statin-induced rhabdomyolysis, as are a subacute progression of low back pain and proximal muscle pain over the ensuing weeks.1,4 A high index of suspicion is necessary for any patient presenting with an elevated CK. The time of statin use before the development of rhabdomyolysis can range from one week to four years, the average being about six months to one year.1,4 This timeframe is shortened when a statin is combined with a fibrate, with an average onset of 32 days.4

Statin pharmacodynamics and pharmacokinetics may play a role in the incidence of myopathy.1,7,8 Lovastatin, simvastatin, and atorvastatin are predominantly metabolized by the hepatic microsomal cytochrome (CYP) 450 3A4 system (simvastatin also has some CYP 3A5 metabolism). Both rosuvastatin and fluvastatin are also metabolized via the CYP450 2C9 system, with fluvastatin having some involvement of CYP 3A4 activity. Pravastatin undergoes sulfation and is hydrophilic lending to a lower risk of myopathy.1,7,8 Concurrent administration of a statin with other drugs metabolized by the same CYP450 isozyme leads to higher statin levels and a greater risk of myopathy.1,9 Many drugs which are substrates for the CYP3A4 isozyme and therefore many potential interactions can occur. Drugs with interactions include the following: fibrates (gemfibrozil > fenofibrate), nicotinic acid, cyclosporine, tacrolimus, azoles, macrolides (erythromycin, clarithromycin), protease inhibitors, verapamil, amiodarone, warfarin, fluoxetine, and diazepam.1,7,9 These agents should be used cautiously along with statins.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Because pravastatin and rosuvastatin are more hydrophilic than other statins, they are thought to have lower myopathy risks, but still cause myopathy.1,4,7,10 Since rosuvastatin is a relatively new agent, there are limited data on it.7 The choice of a statin may be more important in patients with moderate to severe renal dysfunction, since this is also a risk factor for myopathy. Both atorvastatin and fluvastatin have minimal renal excretion.1 Other risk factors for statin myopathy include excessive alcohol consumption, cocaine use, strenuous exercise, grapefruit juice ingestion (>1 quart/day), age over 80 years, hypertension, diabeties, a low body mass index, hypothyroidism, hypertriglyceridemia, hepatic disease, genetic polymorphisms of CYP450 isozymes, multisystem disease, among others.1,4,9 Certain genetic determinants may be associated with statin-associated myopathy risk.9,11

Pipeline Update

In February 2008, a Biological Product License Application (BLA) was submitted to the U.S. Food and Drug Administration (FDA) for the pegylated anti–tumor necrosis factor (TNF)-α monoclonal antibody (MAb), certolizumab pegol (Cimzia), for treating rheumatoid arthritis (RA).12 In April 2008, the agent received FDA approval for treating adults with moderate to severe Crohn’s disease.13 UCB has commenced efforts to develop additional rheumatology indications for certolizumab pegol.14 A pooled safety analysis from the certolizumab studies noted a low incidence of injection site pain and therapy discontinuations due to adverse drug reactions. Common side effects were headache, nasopharyngitis, and upper respiratory infections. A drug application for RA was accepted for review in both Canada and Europe in early 2008.15

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Drug Updates Tagged with:Labeling ChangesMyopathyPharmaceutical ResearchSafety

Related Articles

    Diagnosis: Myopathy

    July 1, 2009

    Presentation and evaluation of metabolic causes

    Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

    December 18, 2017

    Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…

    Case Report: What’s Causing This Severe Case of Rhabdomyolysis?

    August 12, 2020

    Rhabdomyolysis is a clinical syndrome characterized by muscle tissue necrosis and release of intramuscular components into the circulation. Typical manifestations include muscle pain and myoglobinuria, causing dark urine. Serum creatinine kinase (CK) enzyme levels are usually markedly elevated. Severity can range from muscle enzyme elevation in the serum of an otherwise asymptomatic patient to extremely…

    AJPhoto / Science Source

    Tips for Diagnosing Metabolic Myopathies

    September 17, 2019

    When evaluating patients with possible myopathic symptoms, rheumatologists must consider a rare, but important, group of inherited disorders: the metabolic myopathies. However, their diagnosis often remains a challenge. Early recognition of these primary metabolic myopathies is essential to help prevent disease morbidity and mortality from rhabdomyolysis. Here, we focus on the metabolic myopathies that present…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences